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ABSTRACT 
The neuropathology of Alzheimer’s disease (AD) and other tauopathies is characterized 
by filamentous deposits of the microtubule-associated protein tau, but the relationship between 
tau polymerization and neurotoxicity is unknown. Here, we examined effects of filamentous tau 
on fast axonal transport (FAT) using isolated squid axoplasm. Monomeric and filamentous forms 
of recombinant human tau were perfused in axoplasm, and their effects on kinesin- and dynein-
dependent FAT rates evaluated by video microscopy. While perfusion of monomeric tau at 
physiological concentrations showed no effect, tau filaments at the same concentrations 
selectively inhibited anterograde (kinesin-dependent) FAT, triggering the release of conventional 
kinesin from axoplasmic vesicles. Pharmacological experiments indicated that the effect of tau 
filaments on FAT is mediated by protein phosphatase 1 (PP1) and glycogen synthase kinase-3 
(GSK-3) activities. Moreover, deletion analysis suggested that these effects depend on a 
conserved 18-amino acid sequence at the amino terminus of tau.  Interestingly, monomeric tau 
isoforms lacking the C-terminal half of the molecule (including the microtubule binding region) 
recapitulated the effects of full-length filamentous tau.   Our results suggest that pathological tau 
aggregation contributes to neurodegeneration by altering a regulatory pathway for FAT.  
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INTRODUCTION 
Tau is a microtubule-associated protein (MAP) involved in microtubule dynamics and 
maintenance (Amos and Schlieper 2005), and insoluble filamentous tau aggregates form in 
Alzheimer’s disease (AD) and several other neurodegenerative tauopathies (reviewed in 
(Gamblin et al. 2003a). Despite the strong positive correlation between the appearance of 
filamentous tau and neuronal dysfunction (reviewed in (Binder et al. 2005)), no toxic mechanism 
has been directly tied to these structures, and as a result the toxicity of tau filaments remains a 
subject of debate (King 2005).   
In AD, degenerating neurons exhibit alterations in synaptic function (Bell and Claudio 
Cuello 2006; Yoshiyama et al. 2007), the appearance of neuritic varicosities, and the 
mislocalization of various membrane-bound organelles (MBOs), all of which indicate that 
intracellular transport is disrupted in this disease (reviewed in (Morfini et al. 2002a). Given these 
observations, and the central role of tau in AD pathology, a number of investigators have 
explored the effects of monomeric tau on microtubule-dependent fast axonal transport (FAT). 
Although reports have been published arguing both for (Ebneth et al. 1998; Seitz et al. 2002; 
Vershinin et al. 2007), and against (Morfini et al. 2007a) the idea that high levels of soluble tau 
can reduce anterograde FAT by interfering with the attachment of the molecular motor kinesin, 
there is no evidence that such levels of tau are seen in normal or pathological neurons.  
Remarkably, even though the hallmark of AD and other tauopathies is the presence of 
intracellular tau filaments, the biological effects of filamentous tau on FAT have not been 
assessed previously.         
In this paper, we examined the effects of tau filaments on FAT using isolated squid 
axoplasm. Whereas at low, physiologically relevant, ratios of tau to tubulin, monomeric tau has 
 5 
no effect, tau filaments selectively inhibit anterograde, conventional kinesin-dependent fast 
axonal transport (FAT).  Furthermore, deletion experiments indicate that this effect requires the 
first 18 a.a. at the amino terminus of tau, which becomes abnormally exposed upon 
polymerization. Consistent with this notion, monomeric tau isoforms lacking the microtubule-
binding region (MTBR) and the C-terminus mimicked the effect of tau filaments on FAT.  
Finally, we show that tau filaments do not act at the microtubule surface, but rather inhibit 
anterograde FAT by activating protein phosphatase 1 (PP1) and glycogen synthase kinase 3 
(GSK-3). Taken together, our findings reveal a novel gain-of-function mechanism by which the 
formation of tau filaments may play a critical role in AD pathogenesis. 
 
MATERIALS AND METHODS 
Reagents: CREBpp was synthesized and purified (95%) by New England Peptide (Gardner, 
MA). Inhibitor-2 (I-2), SB203580, and okadaic acid were purchased from Calbiochem (San 
Diego, CA). Arachidonic acid (AA; Cayman Chemical, Ann Arbor, MI) was stored at -20°C, and 
working solutions were prepared in 100% ethanol immediately prior to use. Mammalian protease 
inhibitor cocktail was from Sigma (St. Louis, MO).  ING-135 was synthesized as described 
previously (Kozikowski et al. 2007). 
Recombinant Proteins: The full-length tau used in this study (hTau40) corresponds to the 
longest isoform in adult human brain, containing 441 amino acids and four microtubule-binding 
repeats (MTBRs).  K23 is a tau construct lacking both alternatively-spliced N-terminal exons as 
well as all four MTBRs. Tau6D and Tau6P are tau isoforms lacking the MTBR region and the C-
terminus of canonical tau.  The alternative splicing that generates these isoforms occurs in exon 
6, and introduces a unique 11 amino acid sequence followed by a stop codon.  The specific 11 
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amino acids vary depending on whether the splice site is proximal or distal to the beginning of 
exon 6 (Luo et al. 2004).  Tau6D and Tau6P isoforms were generated by restriction digestion and 
ligation of constructs previously described (Luo et al. 2004) and hTau40 (Carmel et al. 1996; 
Gustke et al. 1994).  All other constructs used in this study have been described elsewhere:, Δ2-
18 (Gamblin et al. 2003b), 1-421 (Gamblin et al. 2003c), K23 (Preuss et al. 1997).  All proteins 
were expressed in E. coli and purified by means of an N-terminal poly-histidine tag (Abraha et 
al. 2000; Carmel et al. 1996).   
Immunoblots: Tau constructs were spotted onto nitrocellulose membranes (1 ng/µL, 1 µL per 
spot), blocked with 5% non-fat dry milk in Tris-buffered saline, pH 7.4, and probed with the 
monoclonal antibodies Tau12 (2 ng/mL), Tau5 (20 ng/mL), and Tau46.1 (20 ng/mL), which 
recognize amino acids 9-18, 210-230, and 428-441, respectively (Carmel et al. 1996; Ghoshal et 
al. 2002; Kosik et al. 1988).  Primary antibody binding was detected with HRP-conjugated anti-
mouse secondary antibody (Vector Laboratories, Burlingame, CA) and ECL developing solution 
(GE Healthcare, Amersham, UK). 
Microtubule-binding Assays: Squid optic lobes were dissected and flash frozen in liquid 
nitrogen (Morfini et al. 2007a). 1.5 grams of freshly thawed squid optic lobes was homogenized 
in 2.5 mL of BRB80 buffer (80 mM Pipes, 1 mM MgCl2 and 1 mM EGTA) and 1/100 
mammalian protease inhibitor cocktail (Sigma, St. Louis, MO), plus phosphatase and kinase 
inhibitors (Calbiochem, San Diego, CA) as follows: 1/200 phosphatase inhibitor cocktail II, 200 
mM sodium orthovanadate, 200 nM mycrocystin RR, 50 nM okadaic acid, 100 nM K252a, 100 
nM staurosporine. Squid optic lobe homogenate was prepared at 40C using a glass Dounce 
homogeneizer. This homogenate was centrifuged at 12,500 x g for 20 min at 40C. The 
supernatant fraction was transferred to a new tube, and centrifuged at 125,000 x g for 5 min at 
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40C in a TL100.3 rotor (Beckman, Fullerton, CA). The supernantant (cytosol) was transferred to 
a new tube, adjusted to 20 µM taxol, and incubated at 370 C for 15 min to allow for microtubule 
polymerization. After this step, 200 µL aliquots of microtubule-containing cytosol were 
incubated alone, or with htau40, or K23 tau constructs (5 µM final concentration) for 20 min at 
370 C. Samples were loaded on top of a 60 µL BRB80 buffer plus 20% sucrose cushion and 20 
µM taxol using 1.5 mL microcentrifuge tubes, and centrifuged for 5 min at 125,000 x g at 40C 
using a TLA100.3 rotor (Beckman, Fullerton, CA). Microtubule pellets were resuspended in 200 
µL of BRB80. Pellets and supernatant fractions were adjusted to 1X gel loading buffer (GLB) 
using a 5X GLB stock (0.35 M Tris-HCl pH 6.8, 10% w/v SDS (Sequanal grade, Pierce, 
Rockford, IL), 36% glycerol, 5% ß-mercaptoethanol, 0.01% bromophenol blue).  Membranes 
were also probed with an antibody against tubulin (DM1a, Sigma) to demonstrate the presence of 
microtubules in the pellet samples.   
Tau Polymerization: Tau polymerization was induced using arachidonic acid as previously 
described (King et al. 1999), except that KCl was substituted for NaCl in the polymerization 
buffer.  This substitution did not prevent filament formation (see Fig. 5b-d). Briefly, tau protein 
(4 µM) was incubated at room temperature in reaction buffer (50 mM HEPES, pH 7.6, 50 mM 
KCl, 5 mM DTT) in the presence of 75 µM arachidonic acid (in ethanol vehicle).  Samples of 
soluble tau were prepared for perfusion in the same manner, except that arachidonic acid was 
excluded from the polymerization buffer.  Control mixtures containing AA but lacking tau were 
prepared in parallel.  Final ethanol concentration in all samples was 3.8%.     
 
Electron Microscopy: Polymerization reactions were allowed to proceed for six hours, fixed 
with 2% glutaraldehyde, spotted onto 300 mesh formvar/carbon coated copper grids (Electron 
Microscopy Sciences, Hatfield, PA), and negatively stained with 2% uranyl acetate (King et al. 
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1999).  Samples were examined using a JEOL JEM-1220 electron microscope at 60kV and 
12,000X magnification, and photographs were taken using a MegaScan 794/20 digital camera 
and DigitalMicrograph software version 3.9.3 (Gatan, Pleasanton, CA). 
 
Squid Axoplasm Motility Assays: Axoplasm from squid giant axons (Loligo pealii; Marine 
Biological Laboratory, Woods Hole, MA) was extruded as previously described (Brady et al. 
1985).  All proteins and inhibitors were diluted in ATP-supplemented X/2 buffer (175 mM 
potassium aspartate, 65 mM taurine, 35 mM betaine, 25 mM glycine, 10 mM HEPES, 6.5 mM 
MgCl2, 5 mM EGTA, 1.5 mM CaCl2, 0.5 mM glucose, pH 7.2) for perfusion.  For experiments 
involving tau and their controls, reaction mixtures (containing tau alone, tau and AA, and AA 
alone) were diluted 1:1 in ATP-supplemented X/2 buffer (final tau concentration 2 µM, when 
present).  Motility was analyzed using a Zeiss Axiomat microscope equipped with a 100X, 
1.3 N.A. objective and DIC optics.  Organelle velocities were measured by matching calibrated 
cursor movements to the speed of vesicles moving in the axoplasm (Morfini et al. 2006).  
Purification of membrane vesicle fractions from squid axoplasms: Two "sister" axoplasms 
were prepared from the same animal and incubated with the appropriate effectors (control buffer, 
active GSK-3β, monomeric tau or filamentous tau) as for motility assays in X/2 buffer plus 1 
mM ATP in 25 µL final volume. Active GSK-3β was from Sigma (# G1663). After 40 min 
incubation, axoplasms were transferred, along with perfusion buffer, to low protein binding 1.5 
mL centrifuge tubes containing 200 µL of homogenization buffer [0.25 mM sucrose, 1 mM 
EDTA, 10 mM Hepes, pH 7.4, 1/100 protease inhibitor cocktail (Sigma #P8340), 1/200 
phosphatase inhibitor cocktail set II (Calbiochem # 524627), 2 µM K252a (Calbiochem # 
420298), 1 µM PKI (Upstate # 12-151)], and carefully homogenized by 2 passages through a 
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23G syringe needle and 5 passages through a 27G syringe needle using a 1 mL Hamilton pipette.  
Axoplasm homogenates were adjusted to 30% iodixanol by mixing 200 µL of axoplasm 
homogenates with 300 µL of solution D (50% (w/v) iodixanol, 10 mM MgCl2 in 250 mM 
sucrose). A 500 µL layer of solution E (25% (w/v) iodixanol, 10 mM MgCl2 in 250 mM sucrose) 
and a 100 µL layer of solution F (5% (w/v) iodixanol, 10 mM MgCl2 in 250 mM sucrose) were 
loaded on top of the axoplasm homogenates. Samples were centrifuged at 250,000 x g max for 1 
hour at 40C in an RP55-S Sorvall rotor. 300 µL containing floating vesicles were collected from 
immediately below the 5% iodixanol interface, and 60 µl of 6X loading sample buffer added.  In 
separate experiments, 0.1% Triton X-100 was added to the axoplasm homogenates prior to 
centrifugation to confirm the membranous nature of this fraction. Immunoblots were developed 
using antibodies against kinesin-1 heavy chain (H2, Pfister et al, 1989), dynein intermediate 
chain (rabbit polyclonal V3, a generous gift from Kevin Vaughan) and SNAP-25 (Synaptic 
Systems #111-002). Quantitative immunoblotting was performed as described before (Morfini et 
al, 2006). 
Statistical Analysis.  
All experiments were repeated at least 3 times. Unless otherwise stated, the data was analyzed by 
ANOVA followed by post-hoc Student-Newman-Keul’s test in order to make all possible 
comparisons. Comparison of transport data from axoplasm under different conditions was done 
using a two sample t-test of µ1-µ2 with Datadesk statistical software (Data Description, Inc; 
Ithaca, NY). Data was expressed as mean + s.e.m. and significance was assessed at p values as 
noted. 
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RESULTS 
To evaluate the effect of tau on microtubule-dependent FAT, we used vesicle motility 
assays in isolated squid axoplasm.  In this experimental system, the bi-directional transport of 
membrane-bound organelles (MBOs) can be directly observed by video-enhanced differential 
interference contrast (DIC) microscopy. This preparation preserves the ionic strength and 
complex environment of the cell, and because the axoplasm is isolated from the cell body, 
nuclear effects can be ignored (Brady et al. 1985).  Also, the absence of plasma membrane in this 
preparation allows for the introduction of experimental agents at tightly controlled 
concentrations (Morfini et al. 2007a).  This system was instrumental in the original discovery of 
kinesin-1 (Brady 1985), novel regulatory pathways for FAT (Morfini et al. 2006; Morfini et al. 
2004; Morfini et al. 2002b), and axonal-specific phosphorylation events (Grant et al. 1999).   
Monomeric hTau40 binds to squid microtubules, but does not affect FAT. 
Alternative splicing produces six major tau isoforms in the adult human central nervous 
system.  In a previous study, we assayed monomeric tau constructs derived from the shortest tau 
isoform (352 a.a., hTau23) and established their effects on FAT (Morfini et al. 2007a).  In the 
present study, we chose to use the longest isoform (441 a.a., hTau40), because  of its greater 
propensity to form filaments (Gamblin et al. 2003a).  Unlike hTau23, hTau40 contains two 
alternatively-spliced N-terminal exons (E2 and E3) and four microtubule binding repeats (R1-
R4).  A schematic of each tau construct used in the present study is shown in Fig. 1a.  
Previously, we demonstrated that monomeric hTau23 binds to axonal squid microtubules 
(Morfini et al. 2007a). To rule out species-related  artifacts, we assayed the ability of monomeric 
hTau40 to interact with endogenous squid microtubules. Microtubule-enriched fractions from 
squid optic lobe were prepared in the presence or absence of hTau40.  Following taxol-induced 
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microtubule assembly, microtubules and associated proteins were sedimented by centrifugation, 
and the resulting fractions (supernatants and microtubule-enriched pellets) probed with anti-tau 
antibodies. A tau construct with low binding affinity (K23) was assayed in parallel to control for 
non-specific sedimentation. As observed previously (Morfini et al. 2007a), most K23 remained 
in the supernatant fraction.  In contrast, hTau40 was depleted from the supernatant fraction and 
found in association with the microtubule-enriched pellet fraction (Fig. 1b), indicating that 
monomeric hTau40 can bind to endogenous squid microtubules. 
Microtubule rigidity is increased when tau binds to the microtubule surface, and this 
effect is observable even at low, non-saturating tau concentrations (Felgner et al. 1997; Morfini 
et al. 2007a). As an additional indicator of hTau40’s ability to interact with squid microtubules, 
we perfused axoplasm with tau and then examined the morphology of microtubules at the 
axoplasm periphery.  In the absence of exogenous tau, many of these microtubules exhibited a 
curved appearance (Fig. 2a).  However, perfusion of monomeric hTau40 (2 µM) caused 
peripheral microtubules to acquire a straight, rigid appearance (Fig. 2b), consistent with binding 
of hTau40 to the microtubule surface (Morfini et al. 2007a).  Together with the sedimentation 
assay, these results demonstrate that hTau40 is capable of binding to squid microtubules.   
We next examined the effects of monomeric hTau40 on FAT.  We perfused axoplasm 
with hTau40 at 2 µM, which is within the physiological range for neurons (2-5 µM) (Drubin et 
al. 1985). The concentration of tubulin in squid axoplasm is 50 µM (Morris and Lasek 1984), 
resulting in a tau to tubulin ratio of approximately 1:25.  FAT rates measured between 30 and 50 
min post-perfusion were pooled and compared to axoplasms perfused with control buffer alone. 
As observed for other monomeric tau constructs (Morfini et al. 2007a), perfusion of hTau40 at 2 
µM showed no effect on either anterograde or retrograde FAT (Fig. 3a),  demonstrating that 
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physiological levels of monomeric hTau40 do not impair FAT in this system.   
Perfusion of filamentous tau selectively inhibits anterograde FAT.  
Recombinant hTau40 forms filaments in vitro when incubated with arachidonic acid (reviewed 
in (Gamblin et al. 2003a)), and these filaments are morphologically similar to those isolated from 
Alzheimer’s disease neuronal tissue (King et al. 1999). To determine the effects of filamentous 
tau on FAT, we perfused hTau40 filaments (2 µM) into squid axoplasm and monitored 
anterograde and retrograde FAT rates.  Unlike monomeric tau, hTau40 filaments inhibited 
anterograde, kinesin-dependent FAT rates (Fig. 3b, p≤0.001) when perfused at the same 
concentration as monomeric hTau40 (2µM). Perfusion of axoplasms with polymerization buffer 
alone (see Materials and Methods) had no effect on FAT (data not shown), demonstrating that 
the effects on FAT were due to the presence of filamentous tau.  Significantly, retrograde FAT 
rates remained unaffected, suggesting that the effects of hTau40 filaments on anterograde FAT 
were not due to alterations in microtubule integrity. Supporting this idea, htau40 filaments (2 
µM) did not produce changes in microtubule morphology when perfused into axoplasm, which 
also suggests that filamentous tau does not bind to microtubules (Fig. 2c). Similarly, perfusion of 
equivalent amounts of polymerization buffer (containing arachidonic acid, but no tau) had no 
effect on FAT (not shown).  
The effect of tau filaments on FAT depends upon the extreme N-terminus of tau  
Several studies suggest important functional roles for both the amino and carboxy 
terminus of tau (Amadoro et al. 2006; Amadoro et al. 2004; Brandt et al. 1995; Lee 2005), and 
the study of selected modifications of these domains constitutes an emerging area of interest in 
AD (Gamblin et al. 2003c; Guillozet-Bongaarts et al. 2005). To determine whether these 
domains are involved in FAT inhibition, we assayed two tau constructs, Δ2-18 and 1-421, 
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containing deletions at the extreme amino- and carboxy-terminus, respectively (see Fig. 1a and 
Fig. 4a). These deletions do not normally prevent tau from forming filaments (Berry et al. 2003; 
Gamblin et al. 2003b).  However, the buffer conditions required for axoplasm perfusion (see 
Materials and Methods) differ from the buffer used in previous tau assembly assays.  This led us 
to evaluate the formation of tau filaments under these experimental conditions using electron 
microscopic analysis. As shown in Fig. 4b-d, hTau40, Δ2-18 and 1-421 all form morphologically 
undistinguishable filaments under these buffer conditions (Fig. 4b-d).   
 We then evaluated the effects of Δ2-18 and 1-421 filaments on FAT. Axoplasms 
perfused with monomeric hTau40 (2 µM) were used as an experimental control, because this 
treatment results in FAT rates that are indistinguishable from control buffer alone (see Fig. 3a).  
Filaments composed of hTau40 (hTau40 F) and 1-421 (1-421 F) significantly reduced 
anterograde FAT rates, compared to hTau40 monomer (hTau40 M; *p≤0.0001 by a two-sample t 
test).  In contrast, Δ2-18 filaments (Δ2-18 F) had no effect on FAT (Fig. 5a). Retrograde 
transport was unaffected in all conditions (Fig. 5b). These results suggest that the first 18 a.a. of 
tau are necessary for the inhibitory effect of tau filaments on anterograde FAT. Although the 
magnitude of the 1-421 filament effect was not as great that of hTau40 filaments in the time 
period under analysis, the pattern of inhibition was similar (see Supplemental Fig. 1A) and the 
effect of 1-421filaments was not significantly different from full-length hTau40 filaments in a t-
test.  It remains to be determined if the apparent difference is the result of variability in the 
effective concentration of the two types of filaments, or if some small difference in the structure 
of the 1-421 filaments affects the presentation of the N-terminus. 
Monomeric tau constructs lacking the C-terminal half of the protein recapitulate the effects of 
tau filaments on FAT. 
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 Results from deletion experiments above suggested that the first 18 a.a. at the amino 
terminus of tau are required to elicit the inhibitory effect of tau filaments on FAT. However, 
various full-length tau constructs including the amino terminal 18 a.a. domain do not affect FAT 
when perfused in monomeric, soluble form (Fig 2 and (Morfini et al. 2007a)), suggesting this 
domain is abnormally exposed in filamentous hTau40. Supporting this idea, biochemical studies 
identified a intramolecular interaction between the amino and C-terminus of monomeric tau 
constructs (Horowitz et al. 2006; Jeganathan et al. 2006). These observations led us to evaluate 
the effect of endogenous tau isoforms lacking the C-terminal half of the protein on FAT.  These 
isoforms, Tau6P and Tau6D, are the products of two cryptic splice sites in exon 6 (see Fig. 1a).  
They are identical to canonical tau from amino acids 1-144, at which point splicing introduces a 
unique 11 amino acid sequence followed by a stop codon.  The specific 11 amino acids differ 
depending on whether the splice site is proximal or distal to the beginning of exon 6 (Luo et al. 
2004).  Tau6P and Tau6D terminate prior to the MTBR region, and so are not expected to 
interact with microtubules (Lee et al. 1989) or form filaments (Abraha et al. 2000; von Bergen et 
al. 2000).    When axoplasm was perfused with monomeric Tau6P or Tau6D (2 µM), anterograde 
FAT was inhibited (p ≤ 0.0001), but retrograde transport remained unchanged.  Since the effects 
of these two isoforms were indistinguishable, data from Tau6P and Tau6D were pooled (Fig. 6).   
The inhibitory effect of these tau isoforms was indistinguishable from that of hTau40 filaments, 
indicating that the amino terminus of tau is sufficient to trigger FAT inhibition (see Discussion).       
The effects of tau filaments on FAT are mediated by GSK-3 activity. 
The effect of tau filaments and monomeric 6P/6D tau isoforms on anterograde FAT 
raised questions about the underlying molecular mechanisms.  The effect of tau filaments on 
FAT is unlikely to be due to steric hindrance of kinesin by tau at the microtubule surface, 
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because filamentous tau is not expected to bind to microtubules (Fig. 2C) and Tau6P/6D 
isoforms lack a MTBR domain. Instead, we suspected that FAT inhibition might occur through 
one of the signaling pathways that regulate the activity of the major anterograde motor in this 
system, conventional kinesin  
Several axonal kinases have been identified that play a role in regulating conventional 
kinesin-dependent FAT, including JNK (Morfini et al. 2006), and GSK-3 (Morfini et al. 2002b) 
kinases. JNK phosphorylates kinesin heavy chains (KHCs), which inhibits kinesin-1 binding to 
microtubules and results in reduced anterograde FAT (Morfini et al. 2006).  The effects of 
abnormal JNK activation can be blocked by SB203580 (Morfini et al. 2006), a pharmacological 
inhibitor that acts on JNK2/3 and other members of the stress-activated protein kinase 
(SAPK)/JNK family (Coffey et al. 2002; Morfini et al. 2006).  To determine whether tau 
filaments inhibit anterograde FAT through a mechanism involving JNK activation, we co-
perfused tau filaments with SB203580 (5 µM). Co-perfusion of tau filaments with SB203580 did 
not block the effect of tau filaments on FAT (Fig. 7c; different from soluble tau at p≤0.001), 
indicating this effect is independent of JNK and other SAPK/JNK kinases (i.e., p38s).  
To evaluate whether tau filaments inhibit anterograde FAT through a mechanism 
involving GSK-3 activation, we co-perfused hTau40 filaments (2 µM) with cAMP response 
element-binding protein phosphopeptide (CREBpp; 0.5 mM).  While many kinases 
phosphorylate intact CREB protein, the peptide fragment employed here (KRREILSRRPpSYR) 
is selectively phosphorylated by GSK-3, and therefore acts as a competitive inhibitor of other 
GSK-3 substrates (Wang et al. 1994b).  Perfusion of CREBpp in squid axoplasm alone has no 
effect on FAT, although it effectively blocks the effects of active GSK-3 on kinesin-1-based 
motility (Morfini et al. 2004; Morfini et al. 2002b). Remarkably, co-perfusion of tau filaments 
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and CREBpp blocked tau filament-induced effects on FAT (Fig. 7a), suggesting that the effects 
of the filaments are dependent on GSK-3 activation. CREBpp also blocked the effects of 1-421 
tau filaments, indicating that these filaments act through the same mechanism as filaments of 
full-length hTau40 (see Supplemental Figure 1).   
To confirm that GSK-3 activity is required for tau filaments to inhibit kinesin-dependent 
FAT, we co-perfused tau filaments with the lithium mimetic ING-135 (100 nM), a highly 
specific inhibitor of GSK-3 (Kozikowski et al. 2007) (for the structure of this compound in 
complex with GSK-3β, see Supplemental Figure 2).  As with CREBpp, co-perfusion with ING-
135 blocked the effect of tau filaments (Fig. 7b), and perfusion of ING-135 alone had no effect 
on FAT (data not shown).  Together, these results suggest that the effect of tau filaments on 
anterograde FAT involves activation of axonal GSK-3.     
Phosphorylation of kinesin light chains (KLCs) by GSK-3 triggers the chaperone-
dependent dissociation of kinesin-1 from its cargo (Morfini et al. 2002b; Pigino et al. 2003).  To 
determine whether tau filaments induce the dissociation of kinesin-1 from cargo, we obtained 
“sister” axoplasms from individual animals and treated them with monomeric or filamentous 
hTau40 (2 µM).  For comparison, we treated other axoplasm pairs with control buffer or with 
recombinant, active GSK-3β.  After 40 min of incubation, we isolated axoplasmic vesicle 
fractions and evaluated kinesin-1 levels with an antibody against kinesin heavy chains (KHCs). 
Antibodies recognizing the synaptic integral membrane protein SNAP-25 served as a control for 
equal vesicle protein loading. The recovery of SNAP-25, kinesin-1 and dynein from vesicles was 
blocked by addition of 0.1% Triton X-100 to axoplasm homogenates prior to centrifugation, 
confirming the membranous nature of this fraction (not shown). Perfusion of either filamentous 
tau or active GSK-3β resulted in ≈50% decrease in the amount of kinesin-1 associated with 
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vesicles relative to monomeric tau or control buffer, respectively (p≤0.05 for filamentous tau).  
In contrast, levels of dynein intermediate chain were unaffected (Fig. 8). These results 
demonstrate that both tau filaments and GSK-3 selectively inhibit anterograde FAT by leading to 
dissociation of conventional kinesin-1, but not dynein, from its transported vesicular cargo.  
PP1 activity mediates the inhibitory effect of tau filaments on FAT  
GSK-3 is inactive when phosphorylated (Wang et al. 1994a), and can be activated by 
axonal phosphatases (Morfini et al. 2004; Wang et al. 1994a).  This prompted us to evaluate 
whether the inhibitory effects of tau filaments involve the activity of axoplasmic phosphatases.  
To this end, we co-perfused axoplasm with tau filaments and okadaic acid (100 nM). Okadaic 
acid inhibits two major serine-threonine phosphatases, namely protein phosphatase 1 (PP1) and 
protein phosphatase 2A (PP2A). Concentrations of okadaic acid alone up to 1 µM have no effect 
on FAT (Bloom et al. 1993).  Remarkably, okadaic acid blocked the effect of tau filaments on 
FAT (Fig. 9a), suggesting that tau filament-mediated inhibition of anterograde FAT involves the 
activity of a major serine-threonine phosphatase. To distinguish between PP1 and PP2A activity, 
we co-perfused filaments with 50 nM inhibitor-2 (I-2). I-2 selectively inhibits PP1, but has no 
effect on PP2A, even at micromolar concentrations (Cohen 1991).  When co-perfused with tau 
filaments, I-2 prevented FAT inhibition (Fig. 9b), suggesting that axonal PP1 activity mediates 
the effect of tau filaments on FAT.  
 
DISCUSSION     
We have demonstrated that hTau40 filaments selectively impair anterograde FAT in 
isolated axoplasm, whereas monomeric hTau40 has no effect at the same concentration.  Our 
results provide a novel link between tau aggregation and neuronal dysfunction, and identify a 
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specific gain of function mechanism conferred by the aggregation process.  Further, our studies 
suggest that inhibition of kinesin-1-based motility represents an important pathogenic event in 
AD and other tauopathies.   
We have previously described a signaling pathway that regulates conventional kinesin-
based motility.  In this pathway, increased PP1 activity results in the dephosphorylation and 
activation of axonal GSK-3 (Morfini et al. 2004).  Activated GSK-3 phosphorylates kinesin light 
chains (KLCs), prompting a chaperone-dependent dissociation of kinesin-1 and cargo (Morfini et 
al. 2004; Morfini et al. 2002b).  Results presented here suggest that tau filaments inhibit 
anterograde FAT by triggering this pathway (Fig. 10).  It is possible that tau filaments directly 
activate PP1 in this cascade, since tau reportedly binds to PP1 and stimulates its activity (Liao et 
al. 1998).  However, more work is necessary to determine whether tau filaments act directly on 
PP1, or if additional intermediate components remain undiscovered.  Additionally, some 
feedback from GSK-3 is conceivable, since GSK-3 is a major tau kinase that can also bind 
directly to tau (Sun et al. 2002), and is reported to be abnormally activated in AD (Ferrer et al. 
2005).     
We demonstrated that the inhibitory effect of tau filaments on FAT requires the extreme 
amino terminus of the protein.  A pivotal role for this part of the protein is consistent with studies 
in other experimental systems.  For example, overexpression of tau amino terminus induces cell 
death in cultured neurons through a mechanism involving abnormal kinase activity (Amadoro et 
al. 2006; Amadoro et al. 2004), and expression of the N-terminus of tau induced microtubule 
disassembly in cells exposed to beta-amyloid (King et al. 2006).  Immunological studies indicate 
that loss of the N-terminus is an early event in the maturation of tau fibrillar lesions in AD 
(Horowitz et al. 2004). Our results suggest that such cleavage events may modulate the toxicity 
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of filamentous tau  on FAT.  The amino terminus is also the site of AD-related phosphorylation 
(Lee et al. 2004) and nitration (Reynolds et al. 2006) events, and of the FTDP-17-associated 
mutations R5L (Poorkaj et al. 2002) and R5H (Hayashi et al. 2002).  Analysis of how these 
modifications influence the effects of tau filaments on FAT may provide further insights into 
disease progression. 
Although hTau40 monomer had no effect on FAT at the concentrations tested, monomers 
of Tau6P and Tau6D inhibited anterograde FAT as effectively as hTau40 filaments.  This result 
demonstrates that the N-terminus of tau is sufficient to produce the observed effects on FAT, 
since these isoforms lack the MTBR region and the C-terminal tail of canonical tau.  
Additionally, it raises the question of why hTau40 monomer failed to show the same inhibitory 
effect, even though it contains an intact amino terminus.  Although monomeric hTau40 was first 
thought to exist in an extended conformation (Schweers et al. 1994; Syme et al. 2002), recent 
evidence suggests that tau in solution adopts a globally folded conformation in which the N-
terminus folds in close proximity to the C-terminus (Horowitz et al. 2006; Jeganathan et al. 
2006).  It is possible that this conformation shields the extreme amino terminus, thus preventing 
hTau40 monomer from inhibiting FAT.  In this scenario, polymerization would freeze hTau40 in 
a different conformation in which the N-terminus is exposed.       
With these results, tau joins a growing list of proteins whose pathogenic forms alter 
regulatory pathways for FAT.  Like tau filaments, AD-associated mutations in presenilin-1 
inhibit kinesin-1-based motility through GSK-3 activation (Pigino et al. 2003), whereas 
pathogenic forms of androgen receptor and huntingtin inhibit kinesin-1 dependent transport 
through JNK activation (Morfini et al. 2006).  The current study suggests that AD represents an 
example of a dysferopathy, where alterations in FAT lead to a dying back neuropathy (Morfini et 
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al. 2007b), providing further evidence that alterations in regulatory pathways for FAT represent a 
common pathogenic event in multiple, otherwise apparently unrelated neurodegenerative 
diseases (Morfini et al. 2002a; Morfini et al. 2005).  
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FIGURE LEGENDS  
Figure 1. Schematic and microtubule binding of tau constructs used in this study.  A) The 
longest isoform of tau in the human central nervous system is referred to as hTau40.  Boxes 
represent alternatively spliced exons (E2 and E3), the proline rich region, and the microtubule-
binding repeats (R1-R4).  Δ2-18 and 1-421 are constructs containing N-terminal and C-terminal 
deletions, respectively, and K23 is a construct lacking N-terminal exons and microtubule-binding 
repeats. Tau6P and Tau6D are isoforms that are identical to canonical tau from amino acids 1-
144, at which point alternative splicing introduces 11 unique amino acids (represented by dark 
boxes) followed by a stop codon.  The specific amino acids differ between Tau6P and Tau6D.  
B) Tau constructs (5 µM) were incubated with microtubule-containing squid optic lobe cytosol 
as described in Materials and Methods. Microtubule pellets (P) and supernatant (S) fractions 
were prepared by centrifugation, and analyzed by immunoblot using antibodies against tau 
(Tau5) and tubulin. Note that the K23 tau construct lacking MTBRs is mostly recovered in 
supernatant fractions, consistent with its weak binding to microtubules. In contrast, hTau40 is 
recovered in association with microtubules. Neither construct was recovered in pellet fractions 
when centrifuged in the absence of squid microtubules (data not shown).   
 
Figure 2. The effect of hTau40 on the morphology of axoplasmic squid microtubules. A) After 
perfusion of squid axoplasm with control buffer, individual microtubules can be observed at the 
axoplasm periphery. Many of these microtubules display a gently curving, freely bending 
morphology (white arrows). B) Perfusion of hTau40 at 2 µM dramatically changes the 
morphology of peripheral microtubules to a stiff, linear appearance (white arrows). This effect of 
tau and other MAPs on microtubule stiffness has been previously characterized in vitro (Felgner 
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et al. 1997), and indicates direct binding of hTau40 to endogenous squid microtubules.  C) In 
contrast to monomeric hTau40, perfusion of filamentous hTau40 at 2 µM does not change the 
morphology of peripheral microtubules.  
 
Figure 3.  Effects of soluble and filamentous tau on FAT. Axoplasms were perfused with soluble 
or filamentous recombinant tau (hTau40), and FAT rates (µm/sec) monitored over a period of 50 
min.  Each arrowhead represents a measurement of the average velocity at which particles move 
in the anterograde (►) or retrograde (◄) direction. Graphs depict compiled data from at least 
three separate trials. While soluble hTau40 (2 µM) had no observable effect on either FAT 
direction (A), hTau40 filaments (2 µM) specifically inhibited anterograde FAT in a time-
dependent manner (B).  
 
Figure 4. Characterization of tau filaments. Tau constructs hTau40, Δ2-18, and 1-421 were all 
recognized by Western blot analysis with the antibody Tau5, which recognizes an epitope near 
the middle of the protein (top panel).  Δ2-18 is not recognized by the N-terminal antibody Tau12, 
and the C-terminal antibody Tau46.1 does not recognize 1-421 (lower panel) (A).  Filaments 
generated from 4 µM hTau40 (B), Δ2-18 (C), and 1-421 (D) following five hours of 
polymerization with arachidonic acid.  Fixed samples were negatively stained and viewed by 
electron microscopy.  Representative digital micrographs are shown.  Size bars represent 200 
nm. 
    
Figure 5. Removal of the extreme N-terminus of tau abolishes the effects of tau filaments on 
FAT.  Box plots of FAT rates in axoplasm perfused with 2 µM soluble or filamentous tau.  Data 
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represent pooled measurements taken between 30 and 50 min of observation.  Perfusion with 
filaments composed of hTau40 (hTau40 F) and 1-421 (1-421 F) significantly reduced 
anterograde FAT compared to hTau40 monomer (hTau40 M) rate at (*p≤0.0001 by a 2 sample t 
test).  In contrast, Δ2-18 filaments (Δ2-18 F) failed to inhibit anterograde FAT (A).  Retrograde 
FAT was unaffected in all conditions (B).  Rates for monomeric hTau40 were indistinguishable 
from axoplasm perfused with buffer alone (data not shown). 
 
Figure 6. The N-terminus of tau is sufficient to inhibit anterograde FAT.  Graph representing 
pooled data from axoplasms perfused with either Tau6P or Tau6D (2 µM).  The N-terminus of 
both isoforms is identical to that of hTau40, but they lack the MTBR region and the C-terminus.  
When perfused as monomer into isolated axoplasm, these isoforms inhibit anterograde FAT.  
The effect was not statistically different from inhibition caused by hTau40 filaments. 
 
Figure 7. The effect of tau filaments is mediated by the activity of GSK-3. Co-perfusion of 
hTau40 filaments with phospho-CREB peptide (0.5 mM), a competitive inhibitor of GSK-3, 
blocked the effects of hTau40 filaments on FAT (A). The inhibitory effect of tau filaments on 
FAT was also blocked by co-perfusion with another specific GSK-3 inhibitor, ING-135 (100 
nM; B).  SB203580 (5 µM), a stress-activated protein kinase inhibitor, did not prevent the effects 
of hTau40 filaments on FAT (C).  Perfusion of any of these inhibitors alone showed no effect on 
FAT (data not shown).    
 
Figure 8. Perfusion of active GSK-3β or filamentous tau induces kinesin-1 release from squid 
vesicle fractions. (A) Purified vesicle fractions from individual axoplasms perfused with buffer 
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control or active GSK-3β, and with soluble tau or filamentous tau were immunobloted for 
kinesin-1 heavy chain (KHC), dynein intermediate chain (DIC) and SNAP-25 antibodies. Note 
the dramatic reduction of kinesin-1 from membrane fractions of axoplasms perfused with GSK-
3β and filamentous tau. B) Perfusion of active GSK-3β and filamentous tau reduces kinesin-1 
membrane association by ≅ 50%. Membrane binding values of KHC, DIC and SNAP-25 are 
expressed as the ratio between axoplasms perfused with active GSK-3β over buffer control and 
fibrillar over soluble tau. Values were obtained by using the Image J software from NIH and 
represent the mean ± SEM from three independent experiments. The difference between soluble 
and filamentous tau was significant at p≤0.05 using a two sample t-test of µ1-µ2. 
 
Figure 9.  The effect of tau filaments depends upon PP1 activity.  The inhibitory effect of tau 
filaments on FAT was blocked by co-perfusion with (A) the serine-threonine phosphatase 
inhibitor okadaic acid (100 nM), and (B) the PP1-specific inhibitor I-2 (50 nM).  Perfusion of 
either of these inhibitors alone had no effect on FAT (data not shown).    
 
Figure 10.  Proposed mechanism underlying tau filament-induced inhibition of anterograde 
FAT.  Pharmacological experiments presented here indicate that FAT inhibition requires the 
activity of PP1 and GSK-3.  We have previously described a pathway in which PP1 
dephosphorylates and activates GSK-3, which subsequently phosphorylates kinesin light chains 
(KLCs). Phosphorylation of KLCs, promotes a chaperone-mediated detachment of kinesin-1 
from its transported cargo.  Our results suggest that tau can trigger this cascade when the amino 
terminus of tau is abnormally exposed in the filamentous form.   
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Supplemental Figure 1. The effect of 1-421 tau filaments is mediated by the activity of GSK-3. 
Axoplasms were perfused with filaments of 1-421 tau, and FAT rates (µm/sec) monitored over a 
period of 50 min. (A) Perfusion of 1-421 filaments (2 µM) specifically inhibited anterograde 
FAT in a time-dependent manner  much as seen with filaments made from full-length tau ht40. 
(B) Co-perfusion of 1-421 filaments with phospho-CREB peptide (0.5 mM), a competitive 
inhibitor of GSK-3, blocked the effects of 1-421 filaments on FAT. These data indicate that the 
effects of 1-421 filaments on anterograde FAT are also mediated by activation of GSK-3. Graphs 
depict compiled data from at least three separate trials. 
 
Supplemental Figure 2. Rendering of 5-ING-135 in complex with GSK-3β. This complex 
structure was generated from the available x-ray structure of the protein co-crystallized with 
staurosporine (PDB:1Q3D) with docking of the inhibitor performed using Molegro Virtual 
Docker program.  ING-135 is a derivative of the natural product staurosporine that binds to the 
ATP-binding site of GSK-3, exhibiting an IC50 of  7nM.  
 
 
 
 
 
 
 
 
 












